Weaver Consulting Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Weaver Consulting Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217K	Buy	+1,373	New	+$186K	0.04%	276
2020 Q4	–	Sell	-166	Closed	-$19K	–	916
2020 Q3	$19K	Hold	166	–	–	0.01%	417
2020 Q2	$19K	Buy	166 +42	+34%	+$4.14K	0.01%	397
2020 Q1	$10K	Hold	124	–	–	0.01%	454
2019 Q4	$10K	Hold	124	–	–	0.01%	501
2019 Q3	$11K	Hold	124	–	–	0.01%	468
2019 Q2	$11K	Hold	124	–	–	0.01%	448
2019 Q1	$10K	Buy	+124	New	+$10.5K	﹤0.01%	952

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Weaver Consulting Group's XBI Position: Q2 2026 in Review

Weaver Consulting Group opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,373 shares worth $217K. The stake represents 0.04% of the portfolio and ranks #276 among its holdings. This is a return to the name: Weaver Consulting Group previously reported a position in XBI as recently as Q3 2020.

Weaver Consulting Group first reported a position in XBI in Q1 2019 and has held it in 8 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Weaver Consulting Group held 1,373 shares of State Street SPDR S&P Biotech ETF worth $217K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Weaver Consulting Group position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.04% of Weaver Consulting Group's portfolio in Q2 2026, its #276 holding.
Weaver Consulting Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 8 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Weaver Consulting Group's 13F filing for Q2 2026, filed 29 Jul 2026.